Incidental serous tubal intraepithelial carcinoma and early invasive serous carcinoma in the nonprophylactic setting analysis of a case series

American Journal of Surgical Pathology

Volumn 39, Issue 4, 2015, Pages 442-453

  Morrison, Jane C ^a,b   Blanco, Luis Z ^a,c   Vang, Russell ^a   Ronnett, Brigitte M ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Pathology ^*  (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

Author keywords

fallopian tube; high grade serous carcinoma; ovarian cancer; serous tubal intraepithelial carcinoma

Indexed keywords

TUMOR MARKER;

ADULT; AGED; BIOPSY; CANCER GRADING; CARCINOMA; CARCINOMA IN SITU; CHEMISTRY; EARLY DIAGNOSIS; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENTAL FINDING; MIDDLE AGED; NEOPLASM; OVARY TUMOR; PATHOLOGY; PREDICTIVE VALUE; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; SALPINGECTOMY; TUMOR INVASION; UTERINE TUBE TUMOR;

ADULT; AGED; BIOPSY; CARCINOMA; CARCINOMA IN SITU; EARLY DETECTION OF CANCER; FALLOPIAN TUBE NEOPLASMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INCIDENTAL FINDINGS; MIDDLE AGED; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; OVARIAN NEOPLASMS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; SALPINGECTOMY; TUMOR MARKERS, BIOLOGICAL;

EID: 84925969805     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000352     Document Type: Article

References (42)

1. Colgan TJ, Murphy J, Cole DE, et al. Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status. Am J Surg Pathol. 2001; 25:1283-1289
2. Piek JM, van Diest PJ, Zweemer RP, et al. Dysplastic changes in prophylactically removed Fallopian tubes of women predisposed to developing ovarian cancer. J Pathol. 2001;195:451-456
3. Kauff ND, Satagopan JM, Robson ME, et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med. 2002;346:1609-1615
4. Leeper K, Garcia R, Swisher E, et al. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87:52-56
5. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med. 2002;346:1616-1622
6. Piek JM, Verheijen RH, Kenemans P, et al. BRCA1/2-related ovarian cancers are of tubal origin: a hypothesis. Gynecol Oncol. 2003;90:491
7. Carcangiu ML, Radice P, Manoukian S, et al. Atypical epithelial proliferation in fallopian tubes in prophylactic salpingo-oophorectomy specimens from BRCA1 and BRCA2 germline mutation carriers. Int J Gynecol Pathol. 2004;23:35-40
8. Olivier RI, van Beurden M, Lubsen MA, et al. Clinical outcome of prophylactic oophorectomy in BRCA1/BRCA2 mutation carriers and events during follow-up. Br J Cancer. 2004;90: 1492-1497
9. Marquez RT, Baggerly KA, Patterson AP, et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin Cancer Res. 2005;11:6116-6126
10. Meeuwissen PA, Seynaeve C, Brekelmans CT, et al. Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecol Oncol. 2005;97:476-482
11. Powell CB, Kenley E, Chen LM, et al. Risk-reducing salpingooophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005;23: 127-132
12. Finch A, Shaw P, Rosen B, et al. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol. 2006;100:58-64
13. Finch A, Beiner M, Lubinski J, et al. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296:185-192
14. Hermsen BB, van Diest PJ, Berkhof J, et al. Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. Int J Cancer. 2006;119:1412-1418
15. Lamb JD, Garcia RL, Goff BA, et al. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol. 2006;194:1702-1709
16. Medeiros F, Muto MG, Lee Y, et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Pathol. 2006;30:230-236
17. Callahan MJ, Crum CP, Medeiros F, et al. Primary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25:3985-3990
18. Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationship. Am J Surg Pathol. 2007;31:161-169
19. Lee Y, Miron A, Drapkin R, et al. A candidate precursor to serous carcinoma that originates in the distal fallopian tube. J Pathol. 2007;211:26-35
20. Saleemuddin A, Folkins AK, Garrett L, et al. Risk factors for a serous cancer precursor (p53 signature) in women with inherited BRCA mutations. Gynecol Oncol. 2008;111:226-232
21. Gross AL, Kurman RJ, Vang R, et al. Precursor lesions of highgrade serous ovarian carcinoma: morphological and molecular characteristics. J Oncol. 2010;126295:1-9
22. Kuhn E, Meeker A, Wang TL, et al. Shortened telomeres in serous tubal intraepithelial carcinoma: an early event in ovarian high-grade serous carcinogenesis. Am J Surg Pathol. 2010;34:829-836
23. Kurman RJ, Shih IM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol. 2010;34:433-443
24. Przybycin CG, Kurman RJ, Ronnett BM, et al. Are all pelvic (nonuterine) serous carcinomas of tubal origin? Am J Surg Pathol. 2010;34:1407-1416
25. Cancer Genome Atlas Research N Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474:609-615
26. Vang R, Wheeler JE. Diseases of the fallopian tube and paratubal region. In: Kurman RJ, Ronnett BM, Ellenson LH, eds. Blaustein's Pathology of the Female Genital Tract. New York, NY: Springer; 2011:529-578
27. Gao FF, Bhargava R, Yang H, et al. Clinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin?. Hum Pathol. 2013;44:1534-1543
28. Vang R, Shih IM, Kurman RJ. Fallopian tube precursors of ovarian low- and high-grade serous neoplasms. Histopathology. 2013;62: 44-58
29. Visvanathan K, Vang R, Shaw P, et al. Diagnosis of serous tubal intraepithelial carcinoma based on morphologic and immunohistochemical features: a reproducibility study. Am J Surg Pathol. 2011;35:1766-1775
30. Vang R, Visvanathan K, Gross A, et al. Validation of an algorithm for the diagnosis of serous tubal intraepithelial carcinoma. Int J Gynecol Pathol. 2012;31:243-253
31. Rabban JT, Garg K, Crawford B, et al. Early detection of highgrade tubal serous carcinoma in women at low risk for hereditary breast and ovarian cancer syndrome by systematic examination of fallopian tubes incidentally removed during benign surgery. Am J Surg Pathol. 2014;38:729-742
32. Semmel DR, Folkins AK, Hirsch MS, et al. Intercepting early pelvic serous carcinoma by routine pathological examination of the fimbria. Mod Pathol. 2009;22:985-988
33. Shaw PA, Rouzbahman M, Pizer ES, et al. Candidate serous cancer precursors in fallopian tube epithelium of BRCA1/2 mutation carriers. Mod Pathol. 2009;22:1133-1138
34. Singh N, Gilks CB, Wilkinson N, et al. Assignment of primary site in high-grade serous tubal, ovarian and peritoneal carcinoma: a proposal. Histopathology. 2014;65:149-154
35. Bijron JG, Seldenrijk CA, Zweemer RP, et al. Fallopian tube intraluminal tumor spread from noninvasive precursor lesions: a novel metastatic route in early pelvic carcinogenesis. Am J Surg Pathol. 2013;37:1123-1130
36. Carlson JW, Miron A, Jarboe EA, et al. Serous tubal intraepithelial carcinoma: its potential role in primary peritoneal serous carcinoma and serous cancer prevention. J Clin Oncol. 2008;26:4160-4165
37. Kuhn E, Kurman RJ, Vang R, et al. TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high-grade serous carcinoma-evidence supporting the clonal relationship of the two lesions. J Pathol. 2012;226:421-426
38. Rabban JT, Krasik E, Chen LM, et al. Multistep level sections to detect occult fallopian tube carcinoma in risk-reducing salpingooophorectomies from women with BRCA mutations: implications for defining an optimal specimen dissection protocol. Am J Surg Pathol. 2009;33:1878-1885
39. Rabban JT, Mackey A, Powell CB, et al. Correlation of macroscopic and microscopic pathology in risk reducing salpingooophorectomy: implications for intraoperative specimen evaluation. Gynecol Oncol. 2011;121:466-471
40. Mahe E, Tang S, Deb P, et al. Do deeper sections increase the frequency of detection of serous tubal intraepithelial carcinoma (STIC) in the sectioning and extensively examining the FIMbriated end (SEE-FIM) protocol?. Int J Gynecol Pathol. 2013;32: 353-357
41. Powell CB, Swisher EM, Cass I, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk reducing salpingo-oophorectomy. Gynecol Oncol. 2013;129:364-371
42. Wethington SL, Park KJ, Soslow RA, et al. Clinical outcome of isolated serous tubal intraepithelial carcinomas (STIC). Int J Gynecol Pathol. 2013;23:1603-1611